PE104499A1 - Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes - Google Patents

Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes

Info

Publication number
PE104499A1
PE104499A1 PE1998000535A PE00053598A PE104499A1 PE 104499 A1 PE104499 A1 PE 104499A1 PE 1998000535 A PE1998000535 A PE 1998000535A PE 00053598 A PE00053598 A PE 00053598A PE 104499 A1 PE104499 A1 PE 104499A1
Authority
PE
Peru
Prior art keywords
insulin
diabetes
treatment
tiazolidindiona
pharmaceutical composition
Prior art date
Application number
PE1998000535A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE104499A1 publication Critical patent/PE104499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE1998000535A 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes PE104499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
PE104499A1 true PE104499A1 (es) 2000-01-13

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000535A PE104499A1 (es) 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes

Country Status (30)

Country Link
EP (1) EP0999837A1 (enExample)
JP (1) JP2002504138A (enExample)
KR (1) KR20010013843A (enExample)
CN (1) CN1133431C (enExample)
AP (1) AP1287A (enExample)
AR (2) AR012997A1 (enExample)
AU (1) AU8216398A (enExample)
BG (1) BG104059A (enExample)
BR (1) BR9810444A (enExample)
CA (1) CA2294141A1 (enExample)
CO (1) CO4940454A1 (enExample)
DZ (1) DZ2521A1 (enExample)
EA (1) EA004800B1 (enExample)
GB (1) GB9712866D0 (enExample)
HU (1) HUP0003260A3 (enExample)
ID (1) ID23951A (enExample)
IL (1) IL133143A0 (enExample)
IN (1) IN189723B (enExample)
MA (1) MA26511A1 (enExample)
NO (1) NO996265L (enExample)
OA (1) OA11517A (enExample)
PE (1) PE104499A1 (enExample)
PL (1) PL343123A1 (enExample)
SK (1) SK179399A3 (enExample)
TR (1) TR199903095T2 (enExample)
TW (1) TW587937B (enExample)
UA (1) UA70299C2 (enExample)
UY (1) UY25050A1 (enExample)
WO (1) WO1998057636A1 (enExample)
ZA (1) ZA985237B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
SI1133312T1 (sl) * 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CA2503117C (en) 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
JPH11510508A (ja) * 1995-08-10 1999-09-14 ワーナー−ランバート・コンパニー インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法
PT859608E (pt) * 1995-09-18 2004-06-30 Ligand Pharm Inc Tratamento de niddm com agonistas de rxr

Also Published As

Publication number Publication date
PL343123A1 (en) 2001-07-30
NO996265D0 (no) 1999-12-17
AR015894A1 (es) 2001-05-30
EA004800B1 (ru) 2004-08-26
SK179399A3 (en) 2000-11-07
TW587937B (en) 2004-05-21
DZ2521A1 (fr) 2003-02-08
HUP0003260A3 (en) 2001-12-28
HUP0003260A2 (hu) 2001-05-28
CN1133431C (zh) 2004-01-07
WO1998057636A1 (en) 1998-12-23
CA2294141A1 (en) 1998-12-23
IL133143A0 (en) 2001-03-19
ID23951A (id) 2000-06-08
CN1260715A (zh) 2000-07-19
KR20010013843A (ko) 2001-02-26
AR012997A1 (es) 2000-11-22
TR199903095T2 (xx) 2000-08-21
NO996265L (no) 1999-12-17
BG104059A (en) 2000-10-31
OA11517A (en) 2004-02-04
AU8216398A (en) 1999-01-04
AP1287A (en) 2004-06-26
AP9901718A0 (en) 1999-12-31
IN189723B (enExample) 2003-04-19
MA26511A1 (fr) 2004-12-20
JP2002504138A (ja) 2002-02-05
EA200000042A1 (ru) 2000-08-28
BR9810444A (pt) 2000-09-05
UY25050A1 (es) 2000-09-29
ZA985237B (en) 2000-02-17
CO4940454A1 (es) 2000-07-24
EP0999837A1 (en) 2000-05-17
GB9712866D0 (en) 1997-08-20
UA70299C2 (en) 2004-10-15

Similar Documents

Publication Publication Date Title
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
MY127530A (en) Pharmaceutical composition
WO2001000223A3 (en) Multiple agent diabetes therapy
DE59811840D1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
BR0107564A (pt) Composição de gliburida
FI925522A0 (fi) Menetelmä hypoglykeemisten ja hypokolesteroleemisten oksa- ja tiatsolidiinidionien valmistamiseksi
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
BR9813801A (pt) Composto, composição farmacêutica, e, processos para o tratamento, controle, ou prevenção, em um mamìfero, de diabete mellitus, de hiperglicemia, de hiperlipidemia, de obesidade, de hipercolesterolemia, e, de hipertrigliceridemia.
SE9702305D0 (sv) New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
PE99799A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
ZA975867B (en) Hypoglycemic and hypolipidemic compounds
PE89199A1 (es) Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes
EE04263B1 (et) Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
TR200103041T2 (tr) Yeni farmas”tik maddeler.
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
GB0021784D0 (en) Novel pharmaceutical

Legal Events

Date Code Title Description
FC Refusal